Global Health Ltd Q1 FY26 Earnings Analysis
Published 5 Jul 2026 | Healthcare Services | Market Cap: ₹37.9K Cr
Price
₹1,425
Market Cap
₹37.9K Cr
P/E Ratio
66.2
How does Global Health Ltd rank in Healthcare Services?
Compare Global Health Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Global Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹142 Cr.
Full financials →Earnings Summary
Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26. Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).
📊 Revenue & Sales Performance
- →Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26.
- →Developing hospitals such as Lucknow and Patna show significant momentum towards operational maturity with increasing occupancy and volumes.
- →Expansion projects (South Delhi, Mumbai, Pitampura) are progressing, though expected commissioning timelines are uncertain; FY 2029-2030 is a tentative target.
- →New hospitals and bed capacity expansion (e.g., Noida starting with 300 beds scaling up, Ranchi expansion) will further drive volume growth.
- →Growth in revenue driven by a mix of higher realizations, more complex procedures (like oncology, robotic surgeries), and improved specialty mix.
- →International patient revenue, especially from Gurugram, is growing but remains a smaller portion of revenue.
- →Acquisition strategy is open to complement organic growth, focusing on quality assets that fit Medanta’s ecosystem.
- →Continued investment in technology and hospital build-out expected to support long-term revenue growth.
📈 Profitability & Margins
- →Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).
- →They plan to invest heavily in latest technology and completion of existing hospital build-outs, expecting bulk expenditure in later construction years (Page 17).
- →EBITDA and PAT showed substantial YoY growth: 23% and 50% respectively in Q1 FY26, indicating robust profitability momentum (Page 4).
- →ARPOB growth in mature hospitals expected at 3%-7% annually, supported by increased realization and operational efficiencies (Page 12).
- →Developing hospitals exhibit potential for ARPOB improvement as PPP business grows and operational efficiencies improve (Page 12).
- →Growth driven by increased inpatient volumes, better realizations especially in Gurgaon, and specialty mix adjustments (Pages 4 and 8).
- →No specific EPS guidance given, but net profit margin improved to 15.1% indicating improvement in earnings quality (Page 4).
🏗️ Capital Expenditure Plans
- →Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati. Bulk of this hospital build-out spend occurs in the last year of construction.
- →The company plans to operationalize the new 550-bed Noida hospital starting with about 300 beds, scaling to full capacity based on demand.
- →They are open to acquisitions, including traditional M&A, O&M contracts, and asset-light models, provided the acquisition fits Medanta’s quality standards, geographical strategy, and financial logic.
- →Investment priority includes doubling down on the latest medical technology alongside physical infrastructure expansion.
- →Capex plans include adding 2,000 beds over 3-4 years, with near-term plans to add 1,000 beds supported by technology and clinical team expansion.
💰 Fundraising & Capital Structure
- →The transcript does not mention any specific plans for current or future fundraising through debt or equity.
- →The company highlighted having a strong balance sheet and a comfortable cash position with good cash on hand.
- →Management emphasized focusing on capital deployment towards acquisitions, greenfield projects, and investment in technology, rather than raising new funds at present.
- →No explicit discussion on issuing new equity or debt financing was made during the call.
- →Growth opportunities and capital expenditure are expected to be funded primarily through internal cash flows and existing resources.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Global Health Ltd Q1 FY26 results?
Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26. Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).
What is Global Health Ltd share price analysis?
Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health Ltd planning capital expenditure?
Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.